Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
NCT06520163
Summary
This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) combination therapy (EAP regimen) in mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma (NHL). A total of 99 NHL patients will be enrolled as research subjects and will be randomly allocated in a 2:1 ratio to compare the EAP regimen versus disease-specific chemotherapy mobilization regimen. The primary endpoint is the proportion of patients achieving the ideal collection value after a single collection (CD34+ cells ≥5×10\^6/kg).
Eligibility
Inclusion Criteria: * Diagnosed with non-Hodgkin's lymphoma before enrollment. * Indication for autologous stem cell transplantation (ASCT). * Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1. * Achieved complete remission after multiple courses of chemotherapy. * Life expectancy ≥ 3 months. * Subjects must be able to understand the protocol and sign the informed consent. Exclusion Criteria: * Cardiac function class II or higher or cardiac ejection fraction \< 40%. * Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) more than three times the upper limit of normal (ULN). * Serum creatinine clearance rate ≤ 50%. * Patients with active infection. * History of prior hematopoietic stem cell mobilization.
Conditions3
Interventions4
Related trials
- A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. — Ascentage Pharma Group Inc.
- Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil — Instituto do Cancer do Estado de São Paulo
- Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL — First Affiliated Hospital of Zhejiang University
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML — Children's Hospital of Soochow University
- Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients — The Affiliated People's Hospital of Ningbo University
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients — Institute of Hematology & Blood Diseases Hospital, China
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL — Institute of Hematology & Blood Diseases Hospital, China
- Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML — Institute of Hematology & Blood Diseases Hospital, China
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06520163